12:00 AM
 | 
Aug 03, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RG7159: Completed Phase I/II enrollment

Roche disclosed that last quarter it completed enrollment of 80 patients with indolent and aggressive non-Hodgkin's lymphoma (NHL) in the first arm of the Phase II portion of the open-label, dose-escalation, European Phase I/II BO20999...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >